Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Biogen Inc

BIIB
Current price
194.38 USD +3.66 USD (+1.92%)
Last closed 190.52 USD
Sector Healthcare
Industry Drug Manufacturers - General
Exchange NASDAQ
Capitalization 28 807 641 088 USD
Yield for 12 month -33.03 %
1Y
3Y
5Y
10Y
15Y
BIIB
21.11.2021 - 28.11.2021

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts. Address: 225 Binney Street, Cambridge, MA, United States, 02142

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

301.6 USD

P/E ratio

24.8657

Dividend Yield

Current Year

+9 835 600 000 USD

Last Year

+10 173 400 000 USD

Current Quarter

+2 386 300 000 USD

Last Quarter

+2 530 300 000 USD

Current Year

+7 302 200 000 USD

Last Year

+7 895 100 000 USD

Current Quarter

+1 768 000 000 USD

Last Quarter

+1 870 700 000 USD

Key Figures BIIB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 2 376 999 936 USD
Operating Margin TTM 19.32 %
PE Ratio 24.8657
Return On Assets TTM 4.58 %
PEG Ratio 6.2424
Return On Equity TTM 8.24 %
Wall Street Target Price 301.6 USD
Revenue TTM 9 835 599 872 USD
Book Value 102.14 USD
Revenue Per Share TTM 67.97 USD
Dividend Share
Quarterly Revenue Growth YOY -6.2 %
Dividend Yield
Gross Profit TTM 7 895 100 000 USD
Earnings Share 7.97 USD
Diluted Eps TTM 7.97 USD
Most Recent Quarter IV 2023
Quarterly Earnings Growth YOY -54.9 %
Profit Margin 11.81 %

Dividend Analytics BIIB

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History BIIB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 3:1
Payout Ratio
Last Split Date 18.01.2001
Dividend Date

Stock Valuation BIIB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 24.8657
Forward PE 13.0039
Enterprise Value Revenue 3.5683
Price Sales TTM 2.9289
Enterprise Value EBITDA 17.2165
Price Book MRQ 1.9465

Financials BIIB

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators BIIB

For 52 weeks

196.4 USD 319.76 USD
50 Day MA 221.17 USD
Shares Short Prior Month 2 659 287
200 Day MA 247.57 USD
Short Ratio 2.66
Shares Short 3 552 970
Short Percent 2.76 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

399.12 USD Microsoft Corporation -4.91 (-1.22%)
Detailed analytics

ETF funds


M

MDAXEX

207.85 CHF iShares MDAX UCITS ETF (DE) 0 (0%)
Detailed analytics

Metals


Gold

2175.88 USD Gold +5.94 (+0.27%)
Detailed analytics